Introduction Remission is the ultimate goal in systemic lupus erythematosus (SLE). In this study, we applied four definitions of remission agreed on by an international collaboration (Definitions of ...
Correspondence to Professor Hendrika Bootsma, Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen 9713 GZ, The Netherlands; h.bootsma{at}umcg.nl ...
1 The DANBIO registry and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark Objectives ...
10 Department of Clinical Medicine, University of Bologna, S Orsola-Malpighi Hospital, Bologna, Italy 11 Section of Internal Medicine and Clinical Oncology, Department of Biomedical Sciences and Human ...
Background: Toll-Like Receptors (TLR) and Interleukin-1 Receptors (IL-1R) play a critical role in the innate immune response as microbial sensors, providing a bridge between the innate and adaptive ...
Aims Treating to low disease activity is routine in rheumatoid arthritis, but no comparable goal has been defined for systemic lupus erythematosus (SLE). We sought to define and validate a Lupus Low ...
Department of Pathophysiology, School of Medicine, National University of Athens, Greece Correspondence to: Professor H M Moutsopoulos Department of Pathophysiology, Medical School, University of ...
Background: Since the 2015 GRAPPA treatment recommendations were published, therapeutic options and management strategies for psoriatic arthritis (PsA) have advanced considerably. Objectives: The goal ...
a Rheumatology Unit, City Hospital, Nottingham NG5 1PB, b Department of Public Health Medicine and Epidemiology, Queens Medical Centre, Nottingham Dr O’Reilly. OBJECTIVES (1) To determine the ...
Sodium–glucose cotransporter- 2 inhibitors (SGLT- 2i) have recently been demonstrated to exert profound cardio- and nephroprotection in large cardiovascular outcome trials. They reduce progression of ...